We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply
Read MoreHide Full Article
Pfizer (PFE - Free Report) and partner BioNTech (BNTX - Free Report) announced that they have entered into an agreement with the United States government to supply 105 million doses of their COVID-19 vaccine by this year. Upon receiving these doses, the U.S. government will pay $3.2 billion to the companies.
Per the terms of the agreement, Pfizer and BioNTech will supply three different doses of the vaccine, 30 µg, 10 µg and 3 µg. In fact, the agreement also includes the supply of Pfizer/BioNTech’s Omicron-adapted COVID-19 vaccineif they are granted emergency use authorization (EUA) by the FDA.
The agreement also provides the U.S. government with an option to purchase up to 195 million additional doses of Pfizer/BioNTech’s COVID-19 vaccine, bringing the total number of potential doses to 300 million.
Shares of Pfizer have lost 13.7% in the year so far against the industry’s 4.8% rise.
Image Source: Zacks Investment Research
The supply agreement with the U.S. government should help boost vaccines sales for full-year 2022 for both Pfizer and BioNTech, who jointly share the profits from the sale of the COVID-19 vaccine doses. In May, Pfizer said it expects to record $32 billion from the sales of COVID vaccines in 2022.
Last week, Pfizer and BioNTech announced new data from a phase II/III study, evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates – one monovalent and the other bivalent.
Data from the phase II/III study showed that participants given the booster dose of both the vaccine candidates generated a substantially higher immune response against the Omicron subvariant BA.1 when compared to Comirnaty, Pfizer/BioNTech’s authorized COVID-19 vaccine.
The bivalent vaccine is a combination of Comirnaty and a vaccine candidate targeting the spike protein of the Omicron BA.1 subvariant.
Pfizer has already shared data from studies on its two Omicron-adapted vaccine candidates with regulators, including the FDA, and a request for EUA is planned.
Pfizer and BioNTech have already started manufacturing doses of the two candidates in anticipation of an authorization for use from the FDA. Both companies intend to start delivery of the two vaccine candidates as soon as they gain FDA authorization.
The monovalent and bivalent vaccine candidates have been developed by Pfizer and BioNTech to address the rise of new and evolving Omicron subvariants. Not only do these variants outcompete the BA.1 subvariant but have also shown the potential to evade immune protection, which creates a need for adapted vaccine boosters.
The COVID-19 vaccines developed by Pfizer and BioNTech are based on mRNA technology. Another vaccine based on mRNA technology, which poses stiff competition to the Pfizer/BioNTech vaccine, has been developed by Moderna (MRNA - Free Report) .
Moderna is also working on developing a new Omicron-based COVID-19 vaccine. Earlier this month, Moderna announced data from an ongoing phase II/III study, which evaluated its bivalent COVID-19 vaccine booster candidate, mRNA-1273.214, targeting the Omicron variant.
The clinical data showed that following one month of administration of the 50 µg dose of mRNA-1273.214, a 5.4-fold increase in neutralizing antibodies against the Omicron subvariants, BA.4 and BA.5, was seen in all study participants, regardless of prior infection. In a subset of seronegative participants, the candidate generated a 6.3-fold increase in neutralizing titers against both the Omicron subvariants. Based on these results, Moderna intends to complete the regulatory filing for mRNA-1273.214 in the coming weeks.
This week, the FDA’s Vaccines and Related Biological Products Advisory Committee (“VRBPAC”) voted 19-2 to recommend modifying the current strain composition of available COVID-19 vaccines to target the Omicron variant and its subvariants. If the FDA follows the VRBPAC’s recommendation, which it usually does, Pfizer/BioNTech will need to roll out Omicron-based vaccine boosters to provide better protection from the virus, which has been mutating rapidly.
The Biden government expects to start a booster campaign in October to prepare for an expected surge in infections in autumn. Pfizer’s latest deal with the U.S. government looks like a step in this direction.
Pfizer currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Sesen Bio , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Sesen Bio’s 2022 bottom line have declined from a loss of 46 cents to 44 cents in the past 60 days. Share prices of Sesen Bio have fallen 2.2% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, Sesen Bio delivered an earnings surprise of 100%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply
Pfizer (PFE - Free Report) and partner BioNTech (BNTX - Free Report) announced that they have entered into an agreement with the United States government to supply 105 million doses of their COVID-19 vaccine by this year. Upon receiving these doses, the U.S. government will pay $3.2 billion to the companies.
Per the terms of the agreement, Pfizer and BioNTech will supply three different doses of the vaccine, 30 µg, 10 µg and 3 µg. In fact, the agreement also includes the supply of Pfizer/BioNTech’s Omicron-adapted COVID-19 vaccineif they are granted emergency use authorization (EUA) by the FDA.
The agreement also provides the U.S. government with an option to purchase up to 195 million additional doses of Pfizer/BioNTech’s COVID-19 vaccine, bringing the total number of potential doses to 300 million.
Shares of Pfizer have lost 13.7% in the year so far against the industry’s 4.8% rise.
Image Source: Zacks Investment Research
The supply agreement with the U.S. government should help boost vaccines sales for full-year 2022 for both Pfizer and BioNTech, who jointly share the profits from the sale of the COVID-19 vaccine doses. In May, Pfizer said it expects to record $32 billion from the sales of COVID vaccines in 2022.
Last week, Pfizer and BioNTech announced new data from a phase II/III study, evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates – one monovalent and the other bivalent.
Data from the phase II/III study showed that participants given the booster dose of both the vaccine candidates generated a substantially higher immune response against the Omicron subvariant BA.1 when compared to Comirnaty, Pfizer/BioNTech’s authorized COVID-19 vaccine.
The bivalent vaccine is a combination of Comirnaty and a vaccine candidate targeting the spike protein of the Omicron BA.1 subvariant.
Pfizer has already shared data from studies on its two Omicron-adapted vaccine candidates with regulators, including the FDA, and a request for EUA is planned.
Pfizer and BioNTech have already started manufacturing doses of the two candidates in anticipation of an authorization for use from the FDA. Both companies intend to start delivery of the two vaccine candidates as soon as they gain FDA authorization.
The monovalent and bivalent vaccine candidates have been developed by Pfizer and BioNTech to address the rise of new and evolving Omicron subvariants. Not only do these variants outcompete the BA.1 subvariant but have also shown the potential to evade immune protection, which creates a need for adapted vaccine boosters.
The COVID-19 vaccines developed by Pfizer and BioNTech are based on mRNA technology. Another vaccine based on mRNA technology, which poses stiff competition to the Pfizer/BioNTech vaccine, has been developed by Moderna (MRNA - Free Report) .
Moderna is also working on developing a new Omicron-based COVID-19 vaccine. Earlier this month, Moderna announced data from an ongoing phase II/III study, which evaluated its bivalent COVID-19 vaccine booster candidate, mRNA-1273.214, targeting the Omicron variant.
The clinical data showed that following one month of administration of the 50 µg dose of mRNA-1273.214, a 5.4-fold increase in neutralizing antibodies against the Omicron subvariants, BA.4 and BA.5, was seen in all study participants, regardless of prior infection. In a subset of seronegative participants, the candidate generated a 6.3-fold increase in neutralizing titers against both the Omicron subvariants. Based on these results, Moderna intends to complete the regulatory filing for mRNA-1273.214 in the coming weeks.
This week, the FDA’s Vaccines and Related Biological Products Advisory Committee (“VRBPAC”) voted 19-2 to recommend modifying the current strain composition of available COVID-19 vaccines to target the Omicron variant and its subvariants. If the FDA follows the VRBPAC’s recommendation, which it usually does, Pfizer/BioNTech will need to roll out Omicron-based vaccine boosters to provide better protection from the virus, which has been mutating rapidly.
The Biden government expects to start a booster campaign in October to prepare for an expected surge in infections in autumn. Pfizer’s latest deal with the U.S. government looks like a step in this direction.
Pfizer Inc. Price
Pfizer Inc. price | Pfizer Inc. Quote
Zacks Rank & Stocks to Consider
Pfizer currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Sesen Bio , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Sesen Bio’s 2022 bottom line have declined from a loss of 46 cents to 44 cents in the past 60 days. Share prices of Sesen Bio have fallen 2.2% in the year-to-date period.
Earnings of Sesen Bio beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 69.9%. In the last reported quarter, Sesen Bio delivered an earnings surprise of 100%.